Información del artículo
Resumen
La artritis psoriásica (APs) es una enfermedad inflamatoria crónica cuyos síntomas suelen aparecer después de los cutáneos. Resulta de vital importancia la realización de un diagnóstico y tratamiento precoz de la enfermedad debido al potencial desarrollo de artritis deformante o mutilante. Los tratamientos clásicos de la APs incluyen la utilización de antiinflamatorios no esteroideos, fármacos antirreumáticos modificadores de la enfermedad (FAME), como metotrexato, sulfasalazina o el oro y, últimamente, leflunomida. Las investigaciones sobre la fisiopatología de la psoriasis y de la APs han llevado a la incorporación de los tratamientos biológicos, concretamente los fármacos anti-factor de necrosis tumoral (TNF). Los tres tratamientos más utilizados en APs son etanercept, infliximab y adalimumab. De todos ellos vamos a hacer una revisión sistemática de los principales estudios disponibles de etanercept para el tratamiento de la APs.
Palabras clave:
Anti-TNF
Artritis psoriásica
Etanercept
Terapia biológica
Abstract
Psoriatic arthritis (PA) is a chronic inflammatory condition whose symptoms generally appear after the skin symptoms. Making an early diagnosis and treatment of the disease is of vital importance because of the potential development of mutilating and deforming arthritis. Classical treatments of PA include the use of non-steroid anti-inflammatory drugs, diseasemodifying antirheumatic drugs (DMARD) such as methotrexate, sulfasalazine, or gold, and finally, leflunomide. Research on the pathophysiology of psoriasis and of the PA has led to the incorporation of biological treatments, specifically anti-TNF drugs. The three treatments used most in PA are etanercept, infliximab and adalimumab. Of all these, we are going to make a systematic review of the principal studies available on etanercept for the treatment of PA.
Keywords:
Anti-TNF
Psoriatic arthritis
Etanercept
Biological therapy
El Texto completo está disponible en PDF
Bibliografía
[1.]
J. Koo.
Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment.
Dermatol Clin, 14 (1996), pp. 485-496
[3.]
A. Gottlieb, N.J. Korman, K.B. Gordon, S.R. Feldman, M. Lebwohl, J.Y. Koo, et al.
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics.
J Am Acad Dermatol, 58 (2008), pp. 851-864
[4.]
C. Biondi Oriente, R. Scarpa, A. Pucino, P. Oriente.
Psoriasis and psoriatic arthritis. Dermatological and rheumatological co-operative clinical report.
Acta Derm Venereol Suppl (Stockh), 146 (1989), pp. 69-71
[5.]
D.G. Leonard, J.D. O’Duffy, R.S. Rogers.
Prospective analysis of psoriatic arthritis in patients hospitalized for psoriasis.
Mayo Clin Proc, 53 (1978), pp. 511-518
[6.]
R. Scarpa, P. Oriente, A. Pucino, M. Torella, L. Vignone, A. Riccio, et al.
Psoriatic arthritis in psoriatic patients.
Br J Rheumatol, 23 (1984), pp. 246-250
[7.]
M. Shbeeb, K.M. Uramoto, L.E. Gibson, W.M. O’Fallon, S.E. Gabriel.
The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991.
J Rheumatol, 27 (2000), pp. 1247-1250
[8.]
H. Zachariae, R. Zachariae, K. Blomqvist, S. Davidsson, L. Molin, C. Mork, et al.
Quality of life and prevalence of arthritis reported by 5,795 members of the Nordic Psoriasis Associations. Data from the Nordic Quality of Life Study.
Acta Derm Venereol, 82 (2002), pp. 108-113
[9.]
P.S. Helliwell, W.J. Taylor.
Classification and diagnostic criteria for psoriatic arthritis.
Ann Rheum Dis, 64 (2005), pp. ii3-ii8
[10.]
J. Brockbank, D. Gladman.
Diagnosis and management of psoriatic arthritis.
Drugs, 62 (2002), pp. 2447-2457
[11.]
D.D. Gladman, R. Shuckett, M.L. Russell, J.C. Thorne, R.K. Schachter.
Psoriatic arthritis (PSA)-an analysis of 220 patients.
Q J Med, 62 (1987), pp. 127-141
[12.]
J.C. Torre Alonso, A. Rodríguez Pérez, J.M. Arribas Castrillo, J. Ballina García, J.L. Riestra Noriega, C. López Larrea.
Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients.
Br J Rheumatol, 30 (1991), pp. 245-250
[13.]
K. Wong, D.D. Gladman, J. Husted, J.A. Long, V.T. Farewell.
Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death.
Arthritis Rheum, 40 (1997), pp. 1868-1872
[14.]
D.O. Clegg, D.J. Reda, E. Mejias, G.W. Cannon, M.H. Weisman, T. Taylor, et al.
Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study.
Arthritis Rheum, 39 (1996), pp. 2013-2020
[15.]
M.L. Cuéllar, L.R. Espinoza.
Methotrexate use in psoriasis and psoriatic arthritis.
Rheum Dis Clin North Am, 23 (1997), pp. 797-809
[16.]
M. Farr, G.D. Kitas, L. Waterhouse, R. Jubb, D. Felix-Davies, P.A. Bacon.
Sulphasalazine in psoriatic arthritis: a double-blind placebo-controlled study.
Br J Rheumatol, 29 (1990), pp. 46-49
[17.]
T. Fredriksson, U. Pettersson.
Severe psoriasis - oral therapy with a new retinoid.
Dermatologica, 157 (1978), pp. 238-244
[18.]
R.F. Willkens, H.J. Williams, J.R. Ward, M.J. Egger, J.C. Reading, P.J. Clements, et al.
Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis.
Arthritis Rheum, 27 (1984), pp. 376-381
[19.]
J.P. Kaltwasser, P. Nash, D. Gladman, C.F. Rosen, F. Behrens, P. Jones, et al.
Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial.
Arthritis Rheum, 50 (2004), pp. 1939-1950
[20.]
P. Mease.
Current treatment for psoriatic arthritis and other spondyloarthrities.
Rheum Dis Clin North Am, 32 (2006), pp. 11-20
[21.]
G. Partsch, G. Steiner, B.F. Leeb, A. Dunky, H. Bröll, J.S. Smolen.
Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid.
J Rheumatol, 24 (1997), pp. 518-523
[22.]
E. Fernández-Cruz, D. Alecsandru, C. Rodríguez-Sainz.
Introducción a los fármacos biológicos.
Actas Dermosifiliogr, 99 (2008), pp. 2-6
[23.]
C. Rodríguez Moreno, P. López Vázquez, C. Durán Parrondo, F. Tato Herrero, F. Lado Lado.
Lugar en terapéutica de los medicamentos antagonistas del factor de necrosis tumoral. Parte I: evaluación clínica.
An Med Interna, 23 (2006), pp. 37-45
[24.]
J.L. Sánchez-Carazo.
Presente y futuro de la terapia biológica en Dermatología.
Actas Dermosifiliogr, 99 (2008), pp. 89-90
[25.]
L. Punzi, M. Podswiadek, P. Sfriso, F. Oliviero, U. Fiocco, S. Todesco.
Pathogenetic and clinical rationale for TNF-blocking therapy in psoriatic arthritis.
Autoimmun Rev, 6 (2007), pp. 524-528
[26.]
P.J. Mease.
Current treatment of psoriatic arthritis.
Rheum Dis Clin North Am, 29 (2003), pp. 495-511
[27.]
A.B. Gottlieb.
Etanercept for the treatment of psoriasis and psoriatic arthritis.
Dermatol Ther, 17 (2004), pp. 401-408
[28.]
P.J. Mease, B.S. Goffe, J. Metz, A. VanderStoep, B. Finck, D.J. Burge.
Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial.
Lancet, 356 (2000), pp. 385-390
[29.]
P.J. Mease, A.J. Kivitz, F.X. Burch, E.L. Siegel, S.B. Cohen, P. Ory, et al.
Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression.
Arthritis Rheum, 50 (2004), pp. 2264-2272
[30.]
P.J. Mease, A.J. Kivitz, F.X. Burch, E.L. Siegel, S.B. Cohen, P. Ory, et al.
Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept.
J Rheumatol, 33 (2006), pp. 712-721
[31.]
E.H. Frankel, B.E. Strober, J.J. Crowley, D.P. Fivenson, J.M. Woolley, E.B. Yu, et al.
Etanercept improves psoriatic arthritis patient-reported outcomes: results from EDUCATE.
Cutis, 79 (2007), pp. 322-326
[32.]
A.B. Gottlieb, P.J. Mease, J. Mark Jackson, D. Eisen, H. Amy Xia, C. Asare, et al.
Clinical characteristics of psoriatic arthritis and psoriasis in dermatologists’offices.
J Dermatolog Treat, 17 (2006), pp. 279-287
[33.]
A.B. Gottlieb, L. Kircik, D. Eisen, J.M. Jackson, E.E. Boh, B.E. Strober, et al.
Use of etanercept for psoriatic arthritis in the dermatologic clinic: the Experience Diagnosing, Understanding Care, and Treatment with Etanercept (EDUCATE) study.
J Dermatolog Treat, 17 (2006), pp. 343-352
[34.]
Sobel JM, Grekin S, Yu EB, et al. Psoriatic arthritis patients treated with etanercept reported reductions in caregiver burden and absenteeism - results from the experience diagnosing, understanding care and treatment with etanercept (EDUCATE) trial. Presentado en la 63.ª sesión anual de la American Academy of Dermatology, 18 a 22 de febrero de 2005; Nueva Orleans, LA.
[35.]
A.B. Kimball, J.M. Jackson, J.M. Sobell, E.E. Boh, S. Grekin, E.B. Pharmd, et al.
Reductions in healthcare resources utilization in psoriatic arthritis patients receiving etanercept therapy: results from the educate trial.
J Drugs Dermatol, 6 (2007), pp. 299-306
[36.]
A. Mazzotta, M. Esposito, C. Schipani, S. Chimenti.
Long-term experience with etanercept in psoriatic arthritis patients: A 3-year observational study.
J Dermatolog Treat, 1 (2009), pp. 1-6
[37.]
S.M. Hoy, L.J. Scott.
Etanercept. A review of its use in the management of ankylosing spondylitis and psoriatic arthritis.
Drugs, 67 (2007), pp. 2609-2633
[38.]
N. Woolacott, Y. Bravo Vergel, N. Hawkins, A. Kainth, Z. Khadjesari, K. Misso, et al.
Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.
Health Technol Assess, 10 (2006), pp. 1-239
[39.]
Y. Bravo Vergel, N.S. Hawkins, K. Claxton, C. Asseburg, S. Palmer, N. Woolacott, et al.
The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis.
Rheumatology (Oxford), 46 (2007), pp. 1729-1735
[40.]
I. Olivieri, S. de Portu, C. Salvarani, A. Cauli, E. Lubrano, A. Spadaro, et al.
The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy.
Rheumatology (Oxford), 47 (2008), pp. 1664-1670
[41.]
Sterry W, Ortonne JP, Kirkham B, Robertson D, Estojak J, Molta C, et al. Results of a randomised, double-blind study to evaluate the effi cacy and safety of etanercept in patients with psoriasis and psoriatic arthritis: the PRESTA trial. Presentado en el 5.° congreso anual de la British Association of Dermatologists, 4 a 6 de diciembre de 2008; Londres, Inglaterra.
[42.]
M.S. Heiberg, C. Kaufmann, E. Rodevand, K. Mikkelsen, W. Koldingsnes, P. Mowinckel, et al.
The comparative effectiveness of anti-TNF therapy and methotrexate in patients with psoriatic arthritis: 6 month results from a longitudinal, observational, multicentre study.
Ann Rheum Dis, 66 (2007), pp. 1038-1042
[43.]
Y. Yazici, D. Erkan, M.D. Lockshin.
A preliminary study of etanercept in the treatment of severe, resistant psoriatic arthritis.
Clin Exp Rheumatol, 18 (2000), pp. 732-734
[44.]
M.L. Cuéllar, E.A. Méndez, R.D. Collins, S. Burford, L.R. Espinoza.
Efficacy of etanercept in refractory psoriatic arthritis (PsA).
Arthritis Rheum, 43 (2000), pp. S106
[45.]
O. Elkayam, M. Yaron, D. Caspi.
From wheels to feet: a dramatic response of severe chronic psoriatic arthritis to etanercept.
Ann Rheum Dis, 59 (2000), pp. 839
[46.]
K. De Vlam, R.J. Lories.
Efficacy, effectiveness and safety of etanercept in monotherapy for refractory psoriatic arthritis: a 26-week observational study.
Rheumatology (Oxford), 45 (2006), pp. 321-324
[47.]
D.D. Gladman, V.T. Farewell.
Progression of psoriatic arthritis: role of time varying clinical indicators.
J Rheumatol, 26 (1999), pp. 2409-2413
[48.]
T.A. Luger, J. Barker, J. Lambert, S. Yang, D. Robertson, J. Foehl, et al.
Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate-to-severe psoriasis.
J Eur Acad Dermatol Venereol, 23 (2009), pp. 896-904
[49.]
R.W. Martin, L.A. Wanke.
Etanercept plus a patient education and support system improve health-related quality of life in rheumatoid arthritis patients in a clinical practice setting (abstract).
Arthritis Rheum, 48 (2003), pp. S424
[50.]
N.J. Bansback, R. Ara, N. Barkham, A. Brennan, A.D. Fraser, P. Conway, et al.
Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis.
Rheumatology (Oxford), 45 (2006), pp. 1029-1038
[51.]
P. Nash.
Therapies for axial disease in psoriatic arthritis. A systematic review.
J Rheumatol, 33 (2006), pp. 1431-1434
[52.]
C.T. Ritchlin.
Therapies for psoriatic enthesopathy. A systematic review.
J Rheumatol, 33 (2006), pp. 1435-1438
[53.]
Y. Braun-Moscovici, D. Markovits, A. Rozin, K. Toledano, A.M. Nahir, A. Balbir-Gurman.
Anti-tumor necrosis factor therapy: 6 year experience of a single center in Northern Israel and possible impact on health policy on results.
Isr Med Assoc J, 10 (2008), pp. 277-281
[54.]
L.E. Kristensen, A. Gülfe, T. Saxne, P. Geborek.
Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register.
Ann Rheum Dis, 67 (2008), pp. 364-369
[55.]
L.C. Coates, L.S. Cawkwell, N.WF. Ng, A.N. Bennett, D.J. Bryer, A.D. Fraser, et al.
Sustained response to long-term biologics and switching in psoriatic arthritis: results from real life experience.
Ann Rheum Dis, 67 (2008), pp. 717-719
[56.]
C.T. Chou.
The clinical application of etanercept in Chinese patients with rheumatic diseases.
Mod Rheumatol, 16 (2006), pp. 206-213
[57.]
C. De Felice, A. Mazzotta, M. Esposito, L. Bianchi, S. Chimenti.
High-dose initiation of etanercept in psoriatic arthritis and plaque psoriasis: efficacy, safety and impact on patients’ quality of life.
J Dermatolog Treat, 17 (2006), pp. 355-358
[58.]
A. Spadaro, F. Ceccarelli, R. Scrivo, G. Valesini.
Life-table analysis of etanercept with or without methotrexate in patients with psoriatic arthritis.
Ann Rheum Dis, 67 (2008), pp. 1650-1651
Copyright © 2010. Academia Española de Dermatología y Venereología
